The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.
The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.
复制标题
DOI：
10.3390/jpm12020197
复制
发表时间：
2022-02-01
影响因子：
--
通讯作者：
Grover NS
中科院分区：
文献类型：
--
作者：
Meier JA;Savoldo B;Grover NS
霍奇金淋巴瘤（HL）的治疗与世纪最初描述的时间相比已经有了很大的发展，许多患者现在通过一线治疗治愈。尽管有这些进展，但超过10%的患者在初始治疗后经历疾病进展，复发率甚至更高。直到最近，复发性和/或难治性HL的治疗选择有限，不包括高强度化疗和干细胞挽救。对HL病理生理学的进一步了解，加上更有针对性的治疗方法的出现，重塑了我们对复发性/难治性HL治疗及其预后的看法。因此，人们越来越关注免疫疗法，这些疗法可以重新编程免疫系统，以更好地克服HL中发现的免疫抑制环境，从而改善癌细胞杀伤。特别是，嵌合抗原受体（CAR）T细胞正在成为这一领域有价值的治疗工具。在针对CD 30的抗体-药物缀合物成功的基础上，经工程改造以识别相同抗原的CAR T细胞现在正在到达患者。尽管仍处于起步阶段，但CAR T治疗复发性/难治性HL在早期临床试验中表现出了非凡的前景，即使在既往接受过多线治疗的患者中也有可能获得持久的缓解。在这里，我们将回顾目前关于在HL中使用CAR T细胞的可用数据，优化其有效性的策略，以及这种疗法如何适应HL的治疗模式。
Treatment for Hodgkin lymphoma (HL) has evolved considerably from the time it was originally described in the 19th century with many patients now being cured with frontline therapy. Despite these advances, upwards of 10% of patients experience progressive disease after initial therapy with an even higher percentage relapsing. Until recently there had been limited therapeutic options for relapsed and/or refractory HL outside of highly intensive chemotherapy with stem cell rescue. Improved understanding of the pathophysiology of HL, coupled with the emergence of more targeted therapeutics, has reshaped how we view the treatment of relapsed/refractory HL and its prognosis. With this, there has been an increased focus on immunotherapies that can reprogram the immune system to better overcome the immunosuppressive milieu found in HL for improved cancer cell killing. In particular, chimeric antigen receptor (CAR) T cells are emerging as a valuable therapeutic tool in this area. Building on the success of antibody-drug conjugates directed against CD30, CAR T cells engineered to recognize the same antigen are now reaching patients. Though still in its infancy, CAR T therapy for relapsed/refractory HL has shown exceptional promise in early-stage clinical trials with the potential for durable responses even in patients who had progressed through multiple lines of prior therapy. Here we will review currently available data on the use of CAR T cells in HL, strategies to optimize their effectiveness, and how this therapy may fit into the treatment paradigm of HL going forward.
登录
查看更多内容
影响因子：
168.9
作者：
Abramson, Jeremy S.;Palomba, M. Lia;Siddiqi, Tanya
通讯作者：
Siddiqi, Tanya
影响因子：
2.7
作者：
El Halabi, Layal;Adam, Julien;Ghez, David
通讯作者：
Ghez, David
影响因子：
4.8
作者：
Brice, P;Bouabdallah, R;Colombat, P
通讯作者：
Colombat, P
DOI：
10.1182/asheducation-2008.1.326
发表时间：
2008-01-01
期刊：
Hematology. American Society of Hematology. Education Program
影响因子：
--
作者：
Crump, Michael
通讯作者：
Crump, Michael
影响因子：
4.3
作者：
Cordeiro, Ana;Bezerra, Evandro D.;Bar, Merav
通讯作者：
Bar, Merav